Trial Profile
A retrospective chart review studying safety and efficacy of Nivolumab in patients with advanced hepatocellular carcinoma or cholangiocarcinoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jan 2017 New trial record